Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Pacific Edge Limited ( (PFGTF) ).
Pacific Edge Limited reported a decline in operating revenue to $5.9 million for the first half of FY 26, primarily due to the loss of Medicare coverage for its Cxbladder tests. Despite this setback, the company is strategically positioning itself for a Medicare-led recovery, with expectations of policy changes following a proposed Contractor Advisory Committee meeting in February 2026. The company has strengthened its clinical foundation with new publications and received a favorable pricing decision from CMS, which could expand its market significantly. Pacific Edge is focusing on profitable territories and non-Medicare revenue streams while awaiting the outcome of its Medicare appeals process.
More about Pacific Edge Limited
Pacific Edge Limited is a cancer diagnostics company specializing in urine-based biomarkers for hematuria evaluation. Its primary product, Cxbladder, is focused on the detection and management of bladder cancer, with a significant market presence in the United States.
Find detailed analytics on PFGTF stock on TipRanks’ Stock Analysis page.